Halozyme, Baxter product meets immunodeficiency endpoint

Halozyme Therapeutics Inc. (NASDAQ:HALO) and partner Baxter International Inc. (NYSE:BAX) said a subcutaneous formulation of Gammagard and recombinant human PH20 met the primary endpoint in a Phase III trial to treat primary immunodeficiency disorder (PID). The product, known as HyQ, achieved an acute serious bacterial infection rate of 0.025 infections per patient per year, which met the required efficacy threshold of no more than one infection per patient per year. The trial enrolled 80 patients. Gammagard is an IV IgG antibodies plasma-based therapy. ...